

Respiratory Viruses in Luxembourg (ReViLux)


Weekly report (6 – 12 June 2022)

Executive summary

The sentinel network reported 4.1% consultations for influenza-like illness, thus exceeding the baseline circulation threshold, according to the European Centre for Disease Prevention and Control (ECDC). Within the specimens collected by the sentinel network, Human rhinovirus was the most frequently detected virus over the last four weeks (35.7%), followed by SARS-CoV-2 (31.0%) and Metapneumovirus (9.5%).

Regarding the SARS-CoV-2 genomic surveillance, LNS sequenced 550 specimens from residents in Luxembourg in week 23 (of 2824 total cases in the Grand Duchy of Luxembourg; 19.5%). This meets the ECDC recommendations to detect emerging variants. Including PCR screening results, 1182 national specimens were analysed globally (41.9%).

The Omicron variant remains the dominant one in the representative sample. The Omicron BA.5 lineage is now the dominant one (62.4%), followed by Omicron BA.2 (31.6%).



Introduction

The Laboratoire national de santé, as **National Reference Laboratory for Acute Respiratory Infections in Luxembourg**, performs close surveillance on respiratory viruses, with a special focus on SARS-CoV-2. There are currently two active projects:

- **The Sentinel Surveillance Network.** It provides a broad picture of respiratory diseases affecting the Luxembourgish population, based on its double monitoring system (syndromic and virological).
- **The National SARS-CoV-2 Genomic Surveillance Program.** It enables detailed observation of SARS-CoV-2 mutations and variants through time and space, and also monitoring specific groups of interest.

The objective of the ReViLux is to inform public health actions in Luxembourg.

Sentinel Surveillance Network

The **Sentinel Surveillance Network** aims at monitoring the circulating respiratory viruses, including SARS-CoV-2, and hence underpin public health actions. Following the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) guidance, it focuses on cases of acute respiratory infection (ARI) and influenza-like illness (ILI).

The current influenza season started in week 40/2021, and the history of ILI consultations is displayed in Figure 1. A detailed summary of the number of ARI and ILI cases during the last four weeks is included in Table 1. In the week of study, 4.1% of consultations were reported as ILI, thus exceeding the threshold for baseline circulation, according to ECDC (2.59%).

Table 1. Syndromic surveillance over the last 4 weeks

Week	ARI		ILI		Total consultations
	N	%	N	%	
2022/20	60	15.87	14	3.70	378
2022/21	25	15.62	5	3.12	160
2022/22	14	7.22	3	1.55	194
2022/23	15	8.88	7	4.14	169

ARI: Acute Respiratory Infections; ILI: Influenza-Like Illness.




Figure 1. Percentage of patients with influenza-like illness over the last three seasons

Additionally, a selection of sentinel cases is further studied in order to monitor the circulation of respiratory viruses in the country, as shown in Figure 2. Over the last 4 weeks, the positivity rate was at 60.6%, and the most frequently detected viruses were Human rhinovirus (35.7%), SARS-CoV-2 (31.0%), Metapneumovirus (9.5%) and Parapneumovirus (9.5%). Co-infections were detected in 5 specimens, including 3 involving SARS-CoV-2. These results are displayed more in detail in Table 2.




Figure 2. Distribution of respiratory viruses detected within the Sentinel Network, by two-week periods. Results from last weeks are not yet consolidated.

Co-inf: co-infection; FLU-A: influenza A; FLU-B: influenza B; PIV: parapneumovirus; RSV: respiratory syncytial virus; ADV: adenovirus; MPV: metapneumovirus; HRV: human rhinovirus; SC2: SARS-CoV-2.

Table 2. Distribution of respiratory viruses detected within the Sentinel Network over the last 4 weeks and during the current season.

Virus	Last 4 weeks		Since start of season 21/22	
	N*	%	N*	%
SARS-CoV-2	13	31.0	342	35.6
Influenzavirus A	3	7.1	283	29.5
Human rhinovirus	15	35.7	184	19.2
Influenzavirus B	0	0.0	34	3.5
Metapneumovirus	4	9.5	34	3.5
Parainfluenzavirus	4	9.5	32	3.3
Adenovirus	1	2.4	26	2.7
Respiratory syncytial virus	2	4.8	25	2.6
Total	42	100.0	960	100.0

Co-infection cases counted once for each virus detected.

SARS-CoV-2 Genomic Surveillance

The current sequencing strategy

The National Reference Laboratory for Acute Respiratory Infections at LNS receives SARS-CoV-2 positive samples (nasopharyngeal or oropharyngeal swabs analysed by RT-PCR) from the national network of laboratories and proceeds as follows:

1. Sequencing a representative sample of specimens.
2. Sequencing specimens from target groups (i.e. hospital cases and post-vaccination cases).
3. Sequencing specimens from clusters with high transmission.

The representative sample of specimens is a systematic selection from all SARS-CoV-2 positive cases registered in Luxembourg to detect emerging variants and early increases in their incidence and transmission within the community in Luxembourg. This sample is selected according to the ECDC guidelines.

Since the emergence of the Omicron variant of concern, and given the high incidence rates in the European context, targeted PCR tests are carried systematically in order to get an earlier interim evaluation of the variants in circulation. The PCR kits currently used target the following spike mutations: 69/70del, K417N, N501Y.

SARS-CoV-2 lineages have been assigned based on Rambaut et al. using the Phylogenetic Assignment of Named Global Outbreak LINEages (pangolin) software (4.0.6, designation v1.9). The Pango nomenclature is used in addition to the WHO nomenclature to enable easier visualization of links between any evolving variants and their ancestor.

Screening and sequenced specimens




Figure 3. Flowchart of specimens collected during week 23/2022

In week 23, 2824 new cases were registered in Luxembourg; hence, the minimum sample size required to detect emerging variants at a 2.5% incidence is estimated to be 495 specimens (17.5%).

As shown in Figure 3, of all specimens received from the week of study, 1165 were screened by targeted PCR for the Omicron variant (including 1065 national specimens), in order to enable an earlier detection of potential Omicron cases (see results in the following section). In parallel, the microbial genomics unit at the LNS sequenced 610 specimens, including 550 national ones. The weekly sequencing coverage remains at 19.5% (out of 2824 cases registered in Luxembourg; see coverage trend in Figure 4), which exceeds the recommended sample size. Overall, 1182 national specimens were analysed either by sequencing or screening (41.9%).




Figure 4. National coverage based on weekly number of positive cases in Luxembourg. The coverage from the latest weeks might not be consolidated yet.

Screening results

As shown in Figure 5, the PCR screening suggests that Omicron lineages with the 69/70 deletion (i.e. BA.4 and BA.5) will continue to increase.




Figure 5. Distribution of specimens included in the screening for the Omicron variant by date of collection. Results more recent than the week of study are not yet consolidated.

Circulating lineages detection

The distribution of successfully assigned lineages within the national selection is shown in Figure 6, and it is further detailed in Table 4 (last two weeks). A summary of the VOCs assigned among all specimens sequenced (including non-residents) during the last two weeks and since the beginning of the sequencing activity is shown in Table 5.

The Omicron variant remains the dominant one within the representative sample, the most frequent lineage being Omicron BA.5 (62.4%), followed by Omicron BA.2 (31.6%) and Omicron BA.4 (5.9%).

Table 4. Distribution of SARS-CoV-2 lineages detected within the representative sample during the last two weeks. Previously reported cases might be updated by retrospective analysis.

Lineage	Previous week			Current week		
	N	%	CI %	N	%	CI %
Omicron BA.5	186	40.6	36.1 - 45.1	296	62.4	58.1 - 66.8
Omicron BA.2	248	54.1	49.6 - 58.7	150	31.6	27.5 - 35.8
Omicron BA.4	24	5.2	3.2 - 7.3	28	5.9	3.8 - 8.0
Total	458	100.0	-	474	100.0	-

CI: Confidence Interval at 95%.




Figure 6. Distribution of lineages within the representative sample during the last 10 weeks.

Table 5. Distribution SARS-CoV-2 variants of concern and lineages under monitoring detected within all samples sequenced since the beginning of the pandemic.

Variant	Previous week		Current week		Cumulative count
	N	%	N	%	
Omicron	660	100	524	100	17 628
BA.2.9	45	6.8	23	4.4	1 009
BA.5	70	10.6	119	22.7	206
BA.4	38	5.8	30	5.7	143
BA.2.12.1	50	7.6	24	4.6	136
BA.2.13	8	1.2	1	0.2	41
BA.2.11	0	0.0	0	0.0	2
Delta	0	0.0	0	0.0	13 678
Others	0	0.0	0	0.0	15 006
Total	660	100	524	100	46 312

Clinical and epidemiological factors

In this section, the lineage distribution of all specimens sequenced over the last month is assessed by demographics (sex and age group, Figure 7) and sampling setting (community vs. hospital, Table 6).




Figure 7. Age group and sex distribution of specimens sequenced over the last 4 weeks, by lineage.

Table 6. Comparison of lineage distribution by sampling setting.

Lineage	Community			Hospital		
	Women	Men	Total	Women	Men	Total
Omicron BA.2	71.1%	75.9%	73.4%	67.3%	69.1%	68.2%
Omicron BA.5	18.6%	14.2%	16.5%	17.3%	25.5%	21.5%
Omicron BA.4	10.3%	9.8%	10.1%	15.4%	5.5%	10.3%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Mutation surveillance

In addition to the surveillance of SARS-CoV-2 variants, the LNS monitors the occurrence of SARS-CoV-2 mutations reported to have a clinical and epidemiological relevance. Newly acquired mutations may occur and their early detection might be key to expect changes in the epidemic evolution. Following ECDC guidance, the LNS is currently monitoring a selection of mutations to the spike protein frequently associated to VOCs. As each VOC is characterised by a set of defining mutations, which are expected to be highly present, it is interesting to analyse the non-defining ones. Among the specimens collected over the last four weeks, the following mutations were detected:

- L452Q in at least 7.17% BA.2 specimens (increasing trend), slightly higher than the rest of Europe (5.98%, also on an increasing trend, according to GISAID). These sequences are labelled as Variant of Interest by ECDC.
- 69/70del in at least 4.06% specimens (increasing trend), slightly lower than the rest of Europe (4.3%, on a higher increasing trend, according to GISAID).

References

Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. Retrieved 20 June 2022, from <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>

COVID-19 Data Portal - accelerating scientific research through data. (2021). Retrieved 20 June 2022, from <https://www.covid19dataportal.org/sequences>

Direção-Geral da Saúde. Relatório de Situação. Retrieved 20 June 2022, from <https://covid19.min-saude.pt/relatorio-de-situacao/>

European Centre for Disease Prevention and Control. Guidance for representative and targeted genomic SARS-CoV-2 monitoring – 3 May 2021. ECDC : Stockholm ; 2021

European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern. Retrieved 20 June 2022, from <https://www.ecdc.europa.eu/en/covid-19/variants-concern>

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health. Geneva: World Health Organization; 2021.

GISAID. EpiCoV – Pandemic coronavirus causing COVID-19. Retrieved 5 mai 2022, from <https://www.gisaid.org>

GitHub - cov-lineages/pangolin: Software package for assigning SARS-CoV-2 genome sequences to global lineages. (2021). Retrieved 20 June 2022, from <https://github.com/cov-lineages/pangolin>

Hadfield J., Megill C., Bell S., Huddleston J., Potter B., Callender C. et al. (2018). Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*, 34(23), 4121-4123. doi: 10.1093/bioinformatics/bty407

Instituto Nacional de Saúde Doutor Ricardo Jorge. Diversidade genética do novo coronavírus SARS-CoV-2 (COVID-19) em Portugal. Retrieved 20 June 2022, from <https://insaflu.insa.pt/covid19/>

Rambaut A., Holmes E., O’Toole Á., Hill V., McCrone J., Ruis C. et al. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology*, 5(11), 1403-1407. doi: 10.1038/s41564-020-0770-5

Robert Koch Institut. Aktueller Lage-/Situationsbericht des RKI zu COVID-19. Retrieved 20 June 2022, from https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html;jsessionid=69BC18053F9591C56EB148E463103DB7.internet101

Santé publique France. Coronavirus : chiffres clés et évolution de la COVID-19 en France et dans le Monde. Retrieved 20 June 2022, from <https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde>

Sciensano. COVID-19 – Bulletin épidémiologique hebdomadaire. Retrieved 20 June 2022, from <https://covid-19.sciensano.be/fr/covid-19-situation-epidemiologique>

The Luxembourgish data platform. COVID-19: Rapports hebdomadaires. Retrieved 20 June 2022, from <https://data.public.lu/en/datasets/covid-19-rapports-hebdomadaires/>